San Francisco — Bayer is set to face a second US jury over allegations that its popular glyphosate-based weed killer Roundup causes cancer, six months after the company’s share price was rocked by a $289m verdict in a California state court. A case brought by California resident Edwin Hardeman against the company is scheduled to begin on Monday in federal rather than state court. The trial is also a test case for a larger litigation. More than 760 of the 9,300 Roundup cases nationwide are consolidated in the federal court in San Francisco that is hearing Hardeman’s case. Bayer denies all allegations that Roundup or glyphosate cause cancer, saying decades of independent studies have shown the world’s most widely used weed killer to be safe for human use and noting that regulators globally have approved the product. Under a January ruling by US district judge Vince Chhabria, who presides over the federal litigation, jurors in Hardeman’s case will not initially hear all the evidence pr...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.



Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now